Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgG in AATD
NCT07135427Phase 4Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Prevnar 20 in pneumococcal infection, sponsored by University of Alabama at Birmingham. Primary endpoint: Antibody response at 4 weeks. Started Sep 2025; status: recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07135427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135427.